Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
1. Zorevunersen shows disease-modifying potential for Dravet syndrome. 2. Clinical data suggests durable seizure reductions and cognitive improvements. 3. Biogen collaborates with Stoke Therapeutics in developing zorevunersen. 4. EMPEROR Phase 3 study is actively enrolling patients with Dravet syndrome. 5. Increased awareness of Dravet syndrome emphasized at international epilepsy congress.